Literature DB >> 7848797

The use of bisphosphonates in osteoporosis.

H Fleisch1.   

Abstract

Bisphosphonates comprise a relatively new class of drug developed to inhibit bone resorption. They are used in Paget's disease and tumour bone disease and recently also in osteoporosis. In the latter, they inhibit further bone loss in postmenopausal osteoporosis as well as other types of bone loss, such as that suffered during immobilisation or steroid therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7848797

Source DB:  PubMed          Journal:  Br J Clin Pract        ISSN: 0007-0947


  5 in total

1.  Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy.

Authors:  J M Pouilles; F Tremollieres; C Roux; J L Sebert; C Alexandre; D Goldberg; R Treves; P Khalifa; P Duntze; S Horlait; P Delmas; D Kuntz
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 2.  Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases.

Authors:  C J Rosen; C R Kessenich
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 3.  Current and potential future drug treatments for osteoporosis.

Authors:  S Patel
Journal:  Ann Rheum Dis       Date:  1996-10       Impact factor: 19.103

4.  In vitro inhibition of membrane-mediated calcification by novel phosphonates.

Authors:  D Skrtic; N Eidelman; G Golomb; E Breuer; E D Eanes
Journal:  Calcif Tissue Int       Date:  1996-05       Impact factor: 4.333

Review 5.  Advances in osteoporosis therapy. 2003 update of practical guidelines.

Authors:  Aliya Khan
Journal:  Can Fam Physician       Date:  2003-04       Impact factor: 3.275

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.